All In Biotech

Drug Trial Radar · NCT05330182

LMN-201 for Prevention of C. Difficile Infection Recurrence

A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence

Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 375 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

375

Planned (sponsor's estimate)

Start

Aug 29, 2024

Primary completion

Aug 31, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Lumen Bioscience, Inc.Industry
Sponsor type
Industry
Collaborators
Congressionally Directed Medical Research Programs
First posted
Apr 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.

Conditions

  • Clostridioides Difficile Infection

Interventions

  • LMN-201Drug

    LMN-201 consists of orally delivered whole, dried, non-viable biomass of spirulina (Arthrospira platensis) grown from 4 separate strains, each of which has been engineered to express one of the following therapeutic proteins: * 3 toxin-binding proteins that bind and inhibit C. difficile toxin B (TcdB), an essential virulence factor for C. difficile * 1 lysozyme-like enzyme that selectively degrades the cell wall of C. difficile and causes rapid destruction of the organism

  • PlaceboDrug

    Doses of placebo will be delivered as identical-appearing cornstarch with coloring in size 00, white, opaque, capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants who achieve global cureTime frame: Up to 16 weeks after initiation of therapy

Locations

15 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente

    Escondido, California

  • Gastroenterology Center of Connecticut

    Hamden, Connecticut

  • University of South Florida

    Tampa, Florida

  • Metro Infectious Disease Consultants, LLC

    Burr Ridge, Illinois

  • Baptist Health Research

    Lexington, Kentucky

  • Henry Ford Health System

    Detroit, Michigan

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic - Rochester

    Rochester, Minnesota

  • Weill Cornell Medicine

    New York, New York

  • IMA Clinical Research

    Mount Airy, North Carolina

  • MD Anderson Cancer Center

    Houston, Texas

  • Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC

    Annandale, Virginia

  • University of Virginia School of Medicine

    Charlottesville, Virginia

  • Kaiser Permanente-Mid Atlantic

    Springfield, Virginia

  • UW Health University Hospital

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.